H.C. Wainwright Reiterates Their Buy Rating on Sol-Gel Technologies Ltd (SLGL)


In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Sol-Gel Technologies Ltd (SLGL), with a price target of $21. The company’s shares closed yesterday at $6.64, close to its 52-week low of $5.98.

Selvaraju observed:

“We have valued Sol-Gel based on a discounted cash flow (DCF) analysis. This yields a value of $102M for TWIN, assuming a 50% probability of success, and a $323M valuation for Epsolay, assuming a 60% probability of success.”

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -13.3% and a 24.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Aerpio Pharmaceuticals Inc.

Sol-Gel Technologies Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $21.

See today’s analyst top recommended stocks >>

The company has a one-year high of $16.48 and a one-year low of $5.98. Currently, Sol-Gel Technologies Ltd has an average volume of 21.82K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sol-Gel Technologies Ltd. a clinical-stage dermatology company, which focuses on identifying, developing and commercializing topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts